CagriSema Significantly Reduces HbA1c and Body Weight in REIMAGINE 2 Trial Results

Novo Nordisk A/S (NVO, NOVOB.CO, NOV.DE) disclosed favorable results from the REIMAGINE 2 late-stage trial, revealing that CagriSema achieved superior reductions in HbA1c levels and body weight when compared to semaglutide across all examined dosages in adults managing type 2 diabetes. The dual-component medication combines a long-acting amylin receptor agonist (cagrilintide) with a long-acting GLP-1 receptor agonist (semaglutide) in a fixed-dose formulation.

Superior Clinical Outcomes Against Semaglutide Monotherapy

The 68-week efficacy and safety evaluation demonstrated that CagriSema achieved an HbA1c reduction of 1.91 percentage points alongside a 14.2% body weight reduction. These findings established superiority on both metrics compared to semaglutide administered individually, as well as other single-component therapies. The safety profile remained consistent with expectations for incretin and amylin-based treatments, showing favorable tolerability throughout the trial period. Martin Holst Lange, executive vice president and chief scientific officer at Novo Nordisk, noted that “by combining semaglutide and cagrilintide, we’re seeing superior outcomes in both blood glucose control and weight reduction beyond what each therapy achieves independently.”

Advancing Treatment Options for Type 2 Diabetes

CagriSema is being investigated across two clinical development pathways: the REIMAGINE programme for type 2 diabetes management and the REDEFINE programme for weight management in individuals with overweight or obesity. The global clinical development effort encompasses multiple Phase 3 trials. Building on earlier findings from REIMAGINE 1 and REDEFINE 3 trials, Novo Nordisk intends to engage with regulatory authorities regarding the approval strategy for CagriSema in type 2 diabetes applications.

Path to Regulatory Approval and Future Clinical Presentations

The company submitted CagriSema for weight management indications to the US FDA in December 2025, supported by data from the REDEFINE 1 and REDEFINE 2 pivotal trials. Comprehensive results from the REIMAGINE 2 trial are scheduled for presentation at an upcoming scientific conference in 2026. On the stock exchange, Novo Nordisk shares closed trading down 0.8 percent at $58.93, though overnight trading showed modest gains around 0.4 percent, reaching $59.19.